Vol 6, No 1 (February 23, 2017): Chinese Clinical Oncology

Editorial

Pancreaticoduodenectomy for pancreatic cancer: perspective from the United States
Aslam Ejaz, Jin He
Chinese Clinical Oncology  
2017;
6
(1)
:1
.
Improving clinical outcomes with pembrolizumab in patients with advanced melanoma
Dae Won Kim, Jonathan S. Zager, Zeynep Eroglu
Chinese Clinical Oncology  
2017;
6
(1)
:2
.
PARP inhibitor and platinum agent in triple negative breast cancer: utilizing innovative trial design to bring together something “new” and something “old”
Priyanka Sharma
Chinese Clinical Oncology  
2017;
6
(1)
:3
.
An ICGC major achievement in breast cancer: a comprehensive catalog of mutations and mutational signatures
François Bertucci, Max Chaffanet, Daniel Birnbaum
Chinese Clinical Oncology  
2017;
6
(1)
:4
.
Beginnings of a “gene cloud” definition in hepatocellular carcinoma
Christopher Taylor Barry
Chinese Clinical Oncology  
2017;
6
(1)
:5
.

Original Article

Comparison of short-term outcomes between laparoscopic-assisted and open complete mesocolic excision (CME) for the treatment of transverse colon cancer
Yong Wang, Chuan Zhang, Yi-Fei Feng, Zan Fu, Yue-Ming Sun
Chinese Clinical Oncology  
2017;
6
(1)
:6
.

Review Article

Milestone clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP)
Priya Rastogi, D. Lawrence Wickerham, Charles E. Geyer Jr, Eleftherios P. Mamounas, Thomas B. Julian, Norman Wolmark
Chinese Clinical Oncology  
2017;
6
(1)
:7
.
The prospective of laparoscopic pancreaticoduodenectomy for cancer management
Hendi Maher, Weiwei Jin, Yiping Mou, Henry Davies
Chinese Clinical Oncology  
2017;
6
(1)
:8
.

Commentary

The promise of using histone deacetylase inhibitors in combination treatment against breast cancer and other solid tumors
Nirmal Perera, Alexander Hergovich
Chinese Clinical Oncology  
2017;
6
(1)
:9
.
Commentary on “LncRNA NBR2 engages a metabolic checkpoint by regulating AMPK under energy stress”
Sara Malih, Massoud Saidijam
Chinese Clinical Oncology  
2017;
6
(1)
:10
.

Your View

Future prospect of gallbladder therapy using Hedgehog signaling inhibitor
Hideya Onishi
Chinese Clinical Oncology  
2017;
6
(1)
:11
.
Chromodomain-helicase-DNA-binding protein 4: a novel therapeutic target in liver cancer stem cells
Kouki Nio, Taro Yamashita, Shuichi Kaneko
Chinese Clinical Oncology  
2017;
6
(1)
:12
.

Meet the Professor1

Professor Norman Wolmark: perseverance sometimes pays off
Chao-Xiu (Melanie) He
Chinese Clinical Oncology  
2017;
6
(1)
:13
.

Disclosure:

1. The series “Meet the Professor” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding.